Laurus Labs Limited — Earnings Release 2026

Jul 25, 2025

July 25, 2025

==> picture [191 x 81] intentionally omitted <==

To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS

Dear Sir / Madam,

Sub: Press Release

Please find enclosed the Press Release on the Unaudited Financial Results for the quarter ended June 30, 2025.

Please take the information on record.

Thanking you,

Yours sincerely,

For Laurus Labs Limited

VENKATESWAR Digitally signed by VENKATESWAR REDDY REDDY GOGIREDDY GOGIREDDY Date: 2025.07.25 15:12:21 +05'30'

G. Venkateswar Reddy

Company Secretary & Compliance Officer

Encl: A/a

==> picture [453 x 76] intentionally omitted <==

==> picture [218 x 93] intentionally omitted <==

Press Release

FOR IMMEDIATE RELEASE

25 JULY, 2025

Laurus Labs Announces Q1 FY26 Results Revenues at ₹ 1,570 Cr; EBITDA at ₹ 389 Cr, 24.8% margins

Hyderabad, July 25, 2025: Laurus Labs Ltd. ( Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028 ), a leading research and development driven pharmaceutical and biotech company in India announces its Q1 FY26 results.

Financial Summary

[₹ Crore] except EPS amounts	1Q FY26	1Q FY25	Y-o-Y
Revenues	1,570	1,195	31%
Gross Margins	59.4%	55.1%	4.3%
EBITDA	389	171	127%
EBITDA Margins	24.8%	14.3%	10.5%
PBT	224	18	1144%
Net Proft	163	13	1154%
EPS(Diluted)	3.0	0.2	1400%

Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented;

“We made healthy progress to start the year with increasing contributions from CDMO business and continued advancement of pipeline projects, supported by Generic FDF. We are moving ahead with strong focus on commercial execution realizing the full potential from promising pipeline opportunities, business development and rapidly enhancing scale and technology capabilities.

We also commenced construction of various facilities across CDMO, Generics and FDF. Once complete, these facilities will fortify our ongoing commitment of being a high-quality development and manufacturing partner at scale including advanced therapies. We remain confident in our strategic direction and commitment as the source of sustainable value creation now and well into the future.”

Corporate Office

2[nd] Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India T +91 40 6659 4333, 3980 4333, 2342 0500/501 F +91 40 6659 4320 / 3980 4320

Registered Office

Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com

==> picture [169 x 72] intentionally omitted <==

V V Ravi Kumar, Executive Director & Chief Financial Officer commented;

“We delivered a solid performance in Q1, in line with expectations. We are pleased to see sustained growth momentum fueled by increasing uptake in CDMO deliveries and healthy business fundamentals. We have achieved revenues of ₹ 1,570 Cr, representing 31% growth and EBITDA of ₹ 389 Cr, representing 127% growth. The EBITDA margins improved substantially to 24.8%, supported by continuing operating leverage. Gross margins stood strong at 59.4% due to favorable CDMO mix and ongoing process improvement initiatives.

We will continue to invest fully behind high value business opportunities to drive near and longterm growth and returns for our shareholders.”

Divisional Revenue Performance

[₹ Crore]	1Q FY26	1Q FY25	Y-o-Y
CDMO	522	257	103%
Small molecules	493	214	130%
Bio	29	43	-33%
Generics	1,048	938	12%
API	637	664	-4%
FDF	411	274	50%
Total Revenues	1,570	1,195	31%
ARV Revenues*	647	552	17%

• Includes API and Formulation (FDF) combined revenues

Summary Highlights:

• Delivered strong performance in Q1; Revenues ₹ 1,570 Cr and +31% revenue growth

• Sustained CDMO momentum, expanding collaboration in complex API and supported by growth in Generics

• ₹ 389 Cr EBITDA with a margin of 24.8%, improvement is due to ramp up in CDMO projects and Operating leverage. Gross margins remained strong at 59.4%, improving 10.5% pts over last year on positive product mix

• Commenced construction of new Gene/ADC facility in Hyderabad, and Microbial fermentation facility in Vizag.

Divisional Highlights:

CDMO – Small molecules

• CDMO business reported revenues of ₹ 493 Cr, during Q1FY26; increased by 130%. Growth is driven by several mid-to-late stage NCE deliveries and ramp up from new manufacturing assets

• Sustained demand in high-value and complex small molecule offerings, enhanced technical expertise supporting customer acquisition

• Pipeline momentum remained healthy across clinical and commercial phase; >110 Active pipeline projects (>90 Human health & 20 Animal health/Crop science. On-

2

==> picture [169 x 72] intentionally omitted <==

• going commercial supplies for several products including APIs as well as several intermediates

• We continue to investment in commercial capacity at Vizag site and expanding new R&D site capabilities in Hyderabad for

BIO

• Bio business reported revenues of ₹ 29 Cr, during Q1FY26. Growth impacted by Customer specific scale-up and scheduling issue

• Bio-catalysis platform across small molecule clinical and commercial API projects gaining traction

• Potential longer-term partnership under discussion with new and existing CDMO customers

• Fermentation manufacturing site (Vizag) build up on track as planned and expect the facility to commence operations by 2026 end

Generics

• Generics business reported revenues of ₹ 1,048 Cr, during Q1FY26, increased by 12%. The growth is driven by both ARV & Developed market portfolio within FDF

• Planned capacity availability to support full year API business remains on track

• Revenue scale up from new contracts driving improvements in our utilization rates. Efforts to increase product portfolio and adding more products under CMO

• KRKA JV updates: Groundbreaking ceremony of Finished formulation manufacturing facility in Hyderabad at 19 acres site with a focus to serve new markets including India

• Product filings update:

• DMF filings: Cumulatively, 90 DMFs filed till date

• Developed market FDF filings: 1 product dossiers filed and a total of 3 approvals received (including Tentative approvals). Cumulatively, 88 product filed till date

Quality Highlights:

• We completed 39 Quality audits in Q1. Company has successfully passed audit inspections without critical findings

3

==> picture [169 x 72] intentionally omitted <==

Earnings Conference Call

The company will organize a conference call on Friday, July 25, 2025 at 5:00 p.m. IST to discuss Q1 FY26 results followed by an interactive Q&A session from participants. All participants may join the call by dialing below numbers OR by using Diamond Pass link

Conference Dial-in
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 101 2045
HongKong	+800 964 448
USA	+1 866 746 2133
UK	+0 808 101 1573
Express Join with Diamond Pass	Click here to register

Transcript of the conference call will be available on the Company’s website: www.lauruslabs.com

==> picture [60 x 10] intentionally omitted <==

----- Start of picture text -----

END
----- End of picture text -----

Media Relations

Karthik C T +91 40 3980 4380 | 9030088669 mediarelations@lauruslabs.com

Investors Relations

Vivek Kumar T +91 40 3980 4366 investorrelations@lauruslabs.com

4

==> picture [169 x 72] intentionally omitted <==

About Laurus Labs

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions.

The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 7,042 people, including 2,632+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its “Smart and Green” chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹5,554 crore in revenue in FY2025 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a “BBB” MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices.

Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle “Chemistry for Better Living,” Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Follow @ Laurus Labs on LinkedIn | Twitter | Facebook | Instagram

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

5